Gross Maya, Spencer Ryan J
Department of Obstetrics and Gynecology, University of Wisconsin-Madison School of Medicine and Public Health, USA.
Division of Gynecologic Oncology, University of Wisconsin-Madison School of Medicine and Public Health, USA.
Case Rep Obstet Gynecol. 2022 Oct 25;2022:6579715. doi: 10.1155/2022/6579715. eCollection 2022.
Recurrent cervical cancer has a grim prognosis with 5-year survival <5%. Current treatment options are limited; standards of care such as palliative chemotherapy and surgical resection often provide a small survival advantage. To date, only one targeted agent has FDA approval for the treatment of recurrent cervical cancer. We present the case of a novel application of olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, as single-agent therapy for recurrent metastatic clear cell cervical cancer in a patient with a somatic BRCA2 mutation. The patient had excellent response to therapy with stable disease without evidence of progression until 14 months of therapy, at which time she was switched to an alternative regimen.
复发性宫颈癌预后严峻，5年生存率低于5%。目前的治疗选择有限；姑息化疗和手术切除等标准治疗方法通常只能带来微小的生存优势。迄今为止，只有一种靶向药物获得了美国食品药品监督管理局（FDA）批准用于治疗复发性宫颈癌。我们报告了一例奥拉帕利（一种聚（二磷酸腺苷-核糖）聚合酶（PARP）抑制剂）作为单药疗法用于治疗一名患有体细胞BRCA2突变的复发性转移性透明细胞宫颈癌患者的新应用案例。该患者对治疗反应良好，疾病稳定，在治疗14个月前均无进展迹象，之后她改用了另一种治疗方案。
